Inflammatory disease biotechnology company Rezera (RZRA.US) delays $200 million IPO in the US
Biotechnology company Rezera announced last Thursday that it will postpone its listing.
According to Smart Finance APP, Rezera (RZRA.US), a biotechnology company developing oral NLRP3 inflammation inhibitors and with its pipeline already advanced to Phase III clinical trials, announced last Thursday that it will postpone its listing. The company had previously filed for an IPO, planning to issue 16.7 million shares in a price range of $11–13, aiming to raise $200 million. Pharmaceutical company GSK (GSK.US), as a new investor and its affiliates, committed to subscribing up to $25 million worth of shares, accounting for 13% of this offering.
This Boston, Massachusetts-based company was founded in 2016 and had originally planned to list on Nasdaq under the ticker RZRA. Jefferies, TD Securities, and Cantor Fitzgerald are serving as joint bookrunners for this IPO.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Downside risk toward 1.1000 against US Dollar – UOB
US LNG Exports Reach Record High as Europe and Asia Hope for Winter Price Relief
U.S. liquefied natural gas exports have reached record highs, potentially easing market pressures caused by war-related disruptions.

Light-asset cross-border logistics service provider CloudDepots sets IPO pricing at $5 to $6, aiming to raise up to $17 million
Logistics service provider CloudDepots Holdings has filed for a $17 million initial public offering.

Morgan Stanley: Eurozone GDP Expected to Grow by 1.2% in 2027, with AI and the French Election as Key Factors
Morgan Stanley expects the eurozone's GDP to grow by 1.2% in 2027, close to its potential level, but states that next year will be “unusually decisive.” The three major variables are AI, the French election, and energy shocks.

